Figure 4.

hLM-521 treatment delays albuminuria in Lamb2−/− mice. Mice were untreated or injected with hLM-521 once daily starting at P11 or P12 for 5–7 days. Urine was collected before injection and at various time points thereafter for assessing ACRs (milligrams per gram). In Lamb2−/− mice with albuminuria<9000 before injection, treatment with hLM-521 kept proteinuria low through P18, compared with uninjected Lamb2−/− mice that showed high proteinuria at P18 (4651±6770, n=12 versus 20,826±11,580, n=8; ***P<0.001). At P20 albuminuria in treated mice began to rise but was still significantly lower than that in untreated Lamb2−/− mice (11,696±12,406, n=5 versus 32,711±13,184, n=5; *P<0.05).